Exclusive Summary

• As a highly mature off-patent classic drug, it requires zero market education cost, enabling overseas distributors to achieve rapid sales monetization post-registration.
• Listed as a WHO Essential Medicine and renowned as the clinical 'gold standard' for Treatment-Resistant OCD, it serves the rigid, long-term medication needs of over 100 million OCD patients worldwide.
• The 10mg and 25mg low-dose specifications perfectly fit the clinical consensus of 'start low and titrate slow' for psychiatric treatments, boosting patient safety and adherence.
• With MNCs gradually scaling back production of low-margin legacy drugs causing regional supply disruptions, reliable Chinese manufacturers can strategically step in as highly stable primary or secondary suppliers.
• Backed by China's integrated API-to-FDF industrial chain, the product offers overwhelming cost advantages, providing local partners with lucrative margins and competitive pricing to win public government tenders.